PDF(Pubmed)
Abstract：
UNASSIGNED: Lipid-related risk and residual cardiovascular risk remain high in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). Significant treatment gaps exist in implementation of pluripotent and effective therapies that reduce these risks.
UNASSIGNED: This study evaluates the efficacy and impact of a dedicated, standalone cardiometabolic clinic designed to address treatment gaps through streamlined management and optimization of treatment strategies.
UNASSIGNED: We retrospectively collected data from the first 400 patients with T2D and ASCVD who underwent treatment at the clinic and presented for at least one follow-up visit. These patients were primarily managed for their cardiometabolic risks and received intensified lipid-lowering therapies, including adjunct non-statin therapies.
UNASSIGNED: Significant findings included increased use of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) to 84 % and 65 %, respectively, with 94 % of patients eventually on one therapy and 55 % on dual therapy. Increases in lipid-lowering therapies led to 89 % of patients achieving low-density lipoprotein cholesterol levels below patient-specific thresholds for intensification.
UNASSIGNED: This care model effectively manages high-risk patient needs, achieving significant intensification of lipid-lowering therapies and broad use of cardiometabolic drugs, and highlights the clinic\'s potential to serve as a model for similar high-risk populations.
UNASSIGNED: This study evaluates the efficacy and impact of a dedicated, standalone cardiometabolic clinic designed to address treatment gaps through streamlined management and optimization of treatment strategies.
UNASSIGNED: We retrospectively collected data from the first 400 patients with T2D and ASCVD who underwent treatment at the clinic and presented for at least one follow-up visit. These patients were primarily managed for their cardiometabolic risks and received intensified lipid-lowering therapies, including adjunct non-statin therapies.
UNASSIGNED: Significant findings included increased use of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) to 84 % and 65 %, respectively, with 94 % of patients eventually on one therapy and 55 % on dual therapy. Increases in lipid-lowering therapies led to 89 % of patients achieving low-density lipoprotein cholesterol levels below patient-specific thresholds for intensification.
UNASSIGNED: This care model effectively manages high-risk patient needs, achieving significant intensification of lipid-lowering therapies and broad use of cardiometabolic drugs, and highlights the clinic\'s potential to serve as a model for similar high-risk populations.
摘要：
■2型糖尿病（T2D）和动脉粥样硬化性心血管疾病（ASCVD）患者的脂质相关风险和残余心血管风险仍然很高。在实施降低这些风险的多能有效疗法方面存在显著的治疗差距。
■这项研究评估了专门的，旨在通过简化管理和优化治疗策略解决治疗差距的独立心脏代谢诊所.
■我们回顾性地收集了前400例T2D和ASCVD患者的数据，这些患者在诊所接受了治疗，并进行了至少一次随访。这些患者主要针对其心脏代谢风险进行管理，并接受强化降脂治疗。包括非他汀类药物的辅助治疗。
■显著发现包括增加胰高血糖素样肽-1受体激动剂（GLP1RA）和钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）的使用至84%和65%，分别,94%的患者最终接受一种治疗，55%的患者接受双重治疗。降脂治疗的增加导致89％的患者达到低密度脂蛋白胆固醇水平低于患者特定的强化阈值。
■这种护理模式有效地管理高风险患者的需求，实现显著强化降脂治疗和广泛使用心脏代谢药物，并强调了该诊所作为类似高危人群模型的潜力。
■这项研究评估了专门的，旨在通过简化管理和优化治疗策略解决治疗差距的独立心脏代谢诊所.
■我们回顾性地收集了前400例T2D和ASCVD患者的数据，这些患者在诊所接受了治疗，并进行了至少一次随访。这些患者主要针对其心脏代谢风险进行管理，并接受强化降脂治疗。包括非他汀类药物的辅助治疗。
■显著发现包括增加胰高血糖素样肽-1受体激动剂（GLP1RA）和钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）的使用至84%和65%，分别,94%的患者最终接受一种治疗，55%的患者接受双重治疗。降脂治疗的增加导致89％的患者达到低密度脂蛋白胆固醇水平低于患者特定的强化阈值。
■这种护理模式有效地管理高风险患者的需求，实现显著强化降脂治疗和广泛使用心脏代谢药物，并强调了该诊所作为类似高危人群模型的潜力。
